在积极监测中,β-阻断剂阿提诺洛的使用与前列腺癌升级之间的关联
Ali H Zahalka1,2, Ethan Fram3, Evan Garden1
1Department of Urology Icahn School of Medicine at Mount Sinai New York New York USA.
BJUI compass
|November 14, 2024
概括
使用β-阻断剂阿提诺洛尔可能会降低在积极监测中的男性显著前列腺癌进展的风险. 这一发现表明阿提诺洛尔在治疗低风险前列腺癌方面可能发挥作用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 上腺体信号与前列腺癌的进展有关.
- 像阿提诺洛尔 (atenolol) 这样的β-上腺素抗剂可能会影响这种途径.
研究的目的:
- 调查阿提诺洛尔使用与前列腺癌患者接受主动监测的病理升级风险之间的关联.
- 探索阿提诺洛尔对由β-上腺体信号传递介导的疾病进展的影响.
主要方法:
- 对467名患有低风险或有利的中等风险前列腺癌的男性进行了回顾性队列研究,并进行了积极监测 (2006-2020年).
- 暴露:使用阿提诺洛的持续时间和剂量.
- 结果:在最后的前列腺活检上,病理级组升级 (至GG≥3).
- 分析:考克斯的比例危险回归模型.
主要成果:
- 诊断后使用阿提诺洛尔与病理升级风险降低有关 (HR 0.81).
- 较长的持续时间 (>2年) 和较高的累积剂量 (>730 DDD) 的阿提诺洛尔显示出更明显的降低风险 (HR 0.41和HR 0.32,分别).
- 在诊断前启动阿提诺洛尔提供了比诊断后启动略有更大的保护作用.
结论:
- 使用阿诺洛尔的β-上腺激素阻塞与在积极监测中男性临床显著等级组病理升级的风险降低有关.
- 阿提诺洛尔可能在减轻精选患者前列腺癌进展方面发挥作用.
相关概念视频
01:28Antihypertensive Drugs: Types of β-Blockers
587
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
587
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
530
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
530
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
541
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
541
01:17Antihypertensive Drugs: Action of β1 Blockers
307
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
307
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
407
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
407
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
527
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
527